Medtech Convergence Fund
SV Health Investors is a transatlantic healthcare-focused investment manager investing across therapeutics, medtech and healthcare growth. The firm supports company creation and early- through growth-stage investments, manages specialized funds (including the Dementia Discovery Fund and Medtech Convergence Fund), provides active portfolio management and syndicates strategic partners to advance clinical and commercial development of healthcare innovations.
Industries
Nr. of Employees
small (1-50)
Medtech Convergence Fund
71 Kingsway, London, WC2B 6ST, UK
Portfolio
Acquired by AdaptHealth in a transaction with total consideration including approximately $1.1 billion cash plus stock; SV listed as a shareholder and investor in the transaction.
#Healthcare Growth
Completed an oversubscribed US$112M Series C financing co-led by SV Health Investors (3 Feb 2025). SV partner Jamil M. Beg joined the board in connection with the financing. AdvanCell expanded a strategic collaboration with Eli Lilly (10 Feb 2025) to research and develop Pb-212-based targeted alpha therapies. AdvanCell describes capabilities in Pb-212 production and radiopharmaceutical manufacturing; company press contact listed as Andrew Adamovich, CEO (contact@advancell.com.au; +61 2 8000 4199).
#Therapeutics / Radiopharmaceuticals
Raised $29M Series A-3 with participation from SV’s Medtech Convergence Fund; product is an AI-enabled wearable and monitoring platform for senior care.
#Medtech (AI-enabled senior care)
Closed $100.5M Series B financing with SV Health Investors joining the syndicate (March 2020); SV partner Mike Ross joined the company board in connection with the round.
#Therapeutics (Oncology / Immuno-oncology)
Reported acquisition by MSD (Merck) for up to $3 billion (29 May 2024).
#Therapeutics (Ophthalmology)
Platform company with multiple partnership and licensing arrangements referenced in SV news items.
#Biotech / Discovery platform
Acquired by AdaptHealth in a transaction with total consideration including approximately $1.1 billion cash plus stock; SV listed as a shareholder and investor in the transaction.
#Healthcare Growth
Completed an oversubscribed US$112M Series C financing co-led by SV Health Investors (3 Feb 2025). SV partner Jamil M. Beg joined the board in connection with the financing. AdvanCell expanded a strategic collaboration with Eli Lilly (10 Feb 2025) to research and develop Pb-212-based targeted alpha therapies. AdvanCell describes capabilities in Pb-212 production and radiopharmaceutical manufacturing; company press contact listed as Andrew Adamovich, CEO (contact@advancell.com.au; +61 2 8000 4199).
#Therapeutics / Radiopharmaceuticals
Raised $29M Series A-3 with participation from SV’s Medtech Convergence Fund; product is an AI-enabled wearable and monitoring platform for senior care.
#Medtech (AI-enabled senior care)
Closed $100.5M Series B financing with SV Health Investors joining the syndicate (March 2020); SV partner Mike Ross joined the company board in connection with the round.
#Therapeutics (Oncology / Immuno-oncology)
Reported acquisition by MSD (Merck) for up to $3 billion (29 May 2024).
#Therapeutics (Ophthalmology)
Platform company with multiple partnership and licensing arrangements referenced in SV news items.
#Biotech / Discovery platform